Astellas To Withdraw Blood-Clot Drug From Review To Seek Partner
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma withdrew an application for Japanese approval of its YM150 (darexaban) circulatory disease drug in response to a demand for more studies